PUBLIC COMPANY
save$RIGLRIGEL PHARMACEUTICALS INC
$RIGL45.25-3.64%South San Francisco, CA, USupdated 8h ago
community read0 votes
pipeline
3
marketed
2
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 22Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase4Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- —Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
- phase3Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
- phase3Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
- phase3A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
🐶 Hiring Signal
next earnings Nov 3, 2026
News
- Capricor shares spike on CEO comments; Cytokinetics sues Bristol MyersThe FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.biopharma_dive · 6d ago
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions, and hires, here are the latest comings and goings in the pharma industry.stat · 27d ago
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.biopharma_dive · 3mo ago
- Pfizer and Arvinas give disappointing breast cancer drug to RigelPfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…endpoints · 3mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that